3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
4
Vomiting
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Prostatic Neoplasms
1
Postoperative Nausea and Vomiting
1
Pain, Intractable
1
Oropharyngeal Neoplasms
1
Nausea
1
Lymphoma, Non-Hodgkin
1
Leukemia, Plasma Cell
1
Immunoglobulin Light-chain Amyloidosis
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Cancer Pain
1
Breast Neoplasms
1
Interventions
Dexamethasone
2
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
Melphalan
1
Maintenance
1
Calcium Dobesilate
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Leukemia, Plasma Cell
×
Calcium Dobesilate
×
Clear all
NCT01328236
2011-09-22
Bortezomib
Clinical Service, China
Phase 2
Unknown
20 enrolled